Predictions
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.27
15.06.23
15.06.23
€3.68
15.06.24
15.06.24
54.91%
22:26
22:26
Valneva SE
Start price
Target price
Perf. (%)
€6.06
11.06.23
11.06.23
€7.00
11.06.24
11.06.24
-43.06%
22:26
22:26
Could be worthwhile Investment >10% per year
Very valuable balance sheet
Virbac S.A.
Start price
Target price
Perf. (%)
€293.50
07.06.23
07.06.23
€310.00
07.06.24
07.06.24
19.19%
03.05.24
03.05.24
Could be worthwhile Investment >10% per year
Poxel S.A.
Start price
Target price
Perf. (%)
€0.61
07.06.23
07.06.23
€0.70
07.06.24
07.06.24
-1.48%
03.05.24
03.05.24
Could be worthwhile Investment >10% per year
Agile Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.21
07.06.23
07.06.23
€11.19
07.06.24
07.06.24
0.00%
15.07.23
15.07.23
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€12.80
07.06.23
07.06.23
-
07.06.24
07.06.24
-85.67%
22:26
22:26
Phibro Animal Health Corp. A
Start price
Target price
Perf. (%)
€12.60
03.06.23
03.06.23
-
03.06.24
03.06.24
26.54%
03.05.24
03.05.24
Acorda Therapeutics Cdt
Start price
Target price
Perf. (%)
€0.58
31.05.23
31.05.23
-
31.05.24
31.05.24
-18.97%
02.06.23
02.06.23
Adamis Pharmaceuticals Corp.
Start price
Target price
Perf. (%)
€0.047
29.05.23
29.05.23
-
29.05.24
29.05.24
0.00%
09.02.24
09.02.24
Orthofix Medical Inc.
Start price
Target price
Perf. (%)
€17.30
29.05.23
29.05.23
-
29.05.24
29.05.24
-30.06%
03.05.24
03.05.24
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€5.48
28.05.23
28.05.23
-
28.05.24
28.05.24
-61.64%
29.04.24
29.04.24
Orthofix Medical Inc.
Start price
Target price
Perf. (%)
€18.00
21.05.23
21.05.23
-
21.05.24
21.05.24
-32.78%
03.05.24
03.05.24
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€6.05
20.05.23
20.05.23
-
20.05.24
20.05.24
-62.64%
29.04.24
29.04.24
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€5.88
19.05.23
19.05.23
€7.00
19.05.24
19.05.24
-63.95%
29.04.24
29.04.24
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year